14 May 2020 

French pharmaceutical giant Sanofi’s CEO Paul Hudson has said that the US will likely have first access to its Covid-19 vaccine if it succeeds. In an interview with Bloomberg News, Hudson noted that the US was the first to fund Sanofi’s vaccine research and hence has the right to the largest pre-order.

The Russian Direct Investment Fund (RDIF) and ChemRar Group have reported positive data from a multi-centre clinical trial of antiviral drug favipiravir in patients with Covid-19. Results showed that 60% of the 40 patients treated with the drug tested negative for coronavirus following five days of treatment, two times higher compared to standard therapy.

Takeda is set to initiate a clinical trial in July to test antibodies from recovered patients’ blood plasma as potential Covid-19 treatment, according to Reuters’s citation of  the company’s executives. The trial, which is designed to enrol hundreds of patients, will run for several months.

The University of Birmingham in the UK is set to launch the CATALYST clinical trial to evaluate various drugs for potentially treating Covid-19. Initially, the study will involve four drug and cellular therapies under an adaptive design for rapid investigation of their effectiveness. The researchers will study a series of new drugs, including medicines for existing cancer and inflammatory diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.